Evidence map›Paper›PMID 39825393›Full record

ArticleBioData mining2025

Enriched phenotypes in rare variant carriers suggest pathogenic mechanisms in rare disease patients.

Lane Fitzsimmons, Undiagnosed Diseases Network, Brett Beaulieu-Jones, Shilpa Nadimpalli Kobren

Abstract read
In one paragraph

Article in BioData mining, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lane FitzsimmonsDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA.
Undiagnosed Diseases Network
Brett Beaulieu-JonesDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA. beaulieujones@uchicago.edu.
Shilpa Nadimpalli KobrenDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA. shilpa_kobren@hms.harvard.edu.

Funding

Diagnosing the Unknown for Care and Advancing Science (DUCAS)U2CNS132415 · NINDS · HARVARD MEDICAL SCHOOL · PI Euan A Ashley, ISAAC S. KOHANE · 2023 to 2026
$32.1M
Coordinating Center for the Undiagnosed Diseases NetworkU01HG007530 · NHGRI · HARVARD MEDICAL SCHOOL · PI KOHANE, ISAAC S. · 2014 to 2022
$30.2M
UCLA clinical site for the investigation of undiagnosed disordersU01NS134356 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARTINEZ-AGOSTO, JULIAN, NELSON, STANLEY F. · 2023 to 2023
$936k
Characterizing Population Differences between Clinical Trial and Real World PopulationsR00NS114850 · NINDS · UNIVERSITY OF CHICAGO · PI BEAULIEU-JONES, BRETT K · 2023 to 2025
$740k
National Institutes of Health (NIH) Common Fund U01HG007530NHGRI NIH HHS U01 HG007530NIH National Institute of Neurological Disorders and Stroke (NINDS) U2CNS132415NINDS NIH HHS R00 NS114850NINDS NIH HHS U01 NS134356NINDS NIH HHS U2C NS132415
6 · The paper itself

Abstract

backgroundThe mechanistic pathways that give rise to the extreme symptoms exhibited by rare disease patients are complex, heterogeneous, and difficult to discern. Understanding these mechanisms is critical for developing treatments that address the underlying causes of diseases rather than merely the presenting symptoms. Moreover, the same dysfunctional series of interrelated symptoms implicated in rare recessive diseases may also lead to milder and potentially preventable symptoms in carriers in the general population. Seizures are a common and extreme phenotype that can result from diverse and often elusive pathways in patients with ultrarare or undiagnosed disorders.

methodsIn this pilot study, we present an approach to understand the underlying pathways leading to seizures in patients from the Undiagnosed Diseases Network (UDN) by analyzing aggregated genotype and phenotype data from the UK Biobank (UKB). Specifically, we look for enriched phenotypes across UKB participants who harbor rare variants in the same gene known or suspected to be causally implicated in a UDN patient's recessively manifesting disorder. Analyzing these milder but related associated phenotypes in UKB participants can provide insight into the disease-causing mechanisms at play in rare disease UDN patients.

resultsWe present six vignettes of undiagnosed patients experiencing seizures as part of their recessive genetic condition. For each patient, we analyze a gene of interest: MPO, P2RX7, SQSTM1, COL27A1, PIGQ, or CACNA2D2, and find relevant symptoms associated with UKB participants. We discuss the potential mechanisms by which the digestive, skeletal, circulatory, and immune system abnormalities found in the UKB patients may contribute to the severe presentations exhibited by UDN patients. We find that in our set of rare disease patients, seizures may result from diverse, multi-step pathways that involve multiple body systems.

conclusionsAnalyses of large-scale population cohorts such as the UKB can be a critical tool to further our understanding of rare diseases in general. Continued research in this area could lead to more precise diagnostics and personalized treatment strategies for patients with rare and undiagnosed conditions.

Indexed as

Compound heterozygousRare diseasesRecessive conditionsSeizuresVariant carriers

Identifiers

PMID39825393
PMCPMC11740427

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.